1 ©2022 KARYOPHARM THERAPEUTICS INC. Third Quarter 2022 Financial Results & Business Update November 3, 2022 On Today's Call • Welcome Elhan Webb, CFA, Senior Vice President, Investor Relations • Overview Richard Paulson, President and Chief Executive Officer • Commercial Highlights Sohanya Cheng, Chief Commercial Officer • Pipeline Update Dr. Reshma Rangwala, Chief Medical Officer • Financial Summary and Guidance Michael Mason, Chief Financial Officer • Closing Remarks Richard Paulson, President and Chief ...

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) Q2 2022 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Mike Mason - EVP, CFO & Treasurer Reshma Rangwala - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Peter Lawson - Barclays Mike Ulz - Morgan Stanley Colleen Kusy - Baird Eric Joseph - JP Morgan Ed White - H.C Faisal Khurshid - SVB Securities Operat ...

1 ©2022 KARYOPHARM THERAPEUTICS INC. May 2022 A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its 2022 net product revenue and 2022 non-GAAP research and development and selling, general and administrative expenses ...

1 ©2022 KARYOPHARM THERAPEUTICS INC. May 2022 A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its 2022 net product revenue and 2022 non-GAAP research and development and selling, general and administrative expenses ...

1 ©2022 KARYOPHARM THERAPEUTICS INC. First Quarter 2022 Financial Results & Business Update May 5, 2022 On Today's Call • Welcome Elhan Webb, Senior Vice President, Investor Relations • Overview Richard Paulson, President and Chief Executive Officer • Commercial Highlights Sohanya Cheng, Chief Commercial Officer • Pipeline Update Dr. Reshma Rangwala, Chief Medical Officer Dr. Patricia Judson, Senior Vice President, Medical Strategy • Financial Summary and Guidance Michael Mason, Chief Financial Officer • Cl ...

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Michael Mason - EVP, CFO & Treasurer Reshma Rangwala - Chief Medical Officer Patricia Judson - SVP, Medical Strategy Conference Call Participants Maurice Raycroft - Jefferies Peter Lawson - Barclays Bank Michael Ulz - Morgan Stanley Faisal Khurshid - SVB Leerink Edward White - H ...

1 ©2022 KARYOPHARM THERAPEUTICS INC. A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies March 2022 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its 2022 net product revenues and 2022 non-GAAP research and development and selling, general and administrative expen ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2021 Earnings Conference Call February 8, 2022 8:30 AM ET Company Participants Richard Paulson - President, Chief Executive Officer Sohanya Cheng - Chief Commercial Officer Jatin Shah - Chief Medical Officer Michael Mason - Chief Financial Officer Sarah Connors - Vice President, Corporate Communications Conference Call Participants Maury Raycroft - Jefferies Peter Lawson - Barclays Mike Ulz - Morgan Stanley Steve - RBC Capital Markets Eric Joseph - JP Morgan J ...

1 ©2022 KARYOPHARM THERAPEUTICS INC. 3) Karyoph A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies January 2022 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's preliminary financial information for fourth quarter and full year 2021; guidance on its expected cash runway and 202 ...

1 ©2021 KARYOPHARM THERAPEUTICS INC. Virtual Investor Day December 8, 2021 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its expected cash runway and 2022 revenue and research and development expenses; expectations and plans relating to XPOVIO or any of its drug candidates, if approved, ...